Wegovy vs Zepbound: Two Weekly Injections Compared on Mechanism, Trials and Side Effects

A patient recently told her physician that she had spent an entire lunch break watching two friends argue about which pen was better, each armed with a screenshot of a study neither had read. That argument is now happening at scale. Search interest in wegovy vs zepbound has climbed since the first head-to-head randomized trial between the two molecules, tirzepatide and semaglutide, was published in the New England Journal of Medicine in May 2025, and it has stayed high as both medicines collected new approvals well beyond the bathroom scale.

As of mid-2026, the picture is clearer than the social media version suggests, and also more interesting. One medicine has the bigger average number on the scale. The other has the strongest proof for protecting the heart. Neither is a shortcut, and both ask the same things of the person using them: patience through a gradual dose escalation, tolerance of a queasy first few months, and a long view.

This explainer walks through how each works, what the trials actually measured, where the evidence is strong and where it thins out, and the signs that mean you should call your clinician rather than a group chat.

What changed recently in the Wegovy vs Zepbound debate

Three developments explain why this comparison is trending rather than fading.

First, the trial. For years, people compared Wegovy and Zepbound by lining up results from separate studies with different participants, lengths and definitions. That is a weak way to compare anything. In May 2025, SURMOUNT-5, a randomized trial that enrolled 751 adults with obesity and without diabetes, directly assigned participants to one medicine or the other for 72 weeks. Tirzepatide produced an average body-weight reduction of 20.2 percent versus 13.7 percent for semaglutide. It was an open-label study, meaning participants and investigators knew which pen was being used, which matters for interpreting side-effect reporting, though weight itself is an objective measure.

Second, the labels widened. In March 2024 the US Food and Drug Administration added a cardiovascular indication to Wegovy, based on the SELECT trial, which showed a 20 percent relative reduction in major adverse cardiovascular events (heart attack, stroke or cardiovascular death) among adults with existing heart disease and overweight or obesity. In December 2024, Zepbound became the first medicine approved for moderate-to-severe obstructive sleep apnea in adults with obesity, a condition in which breathing repeatedly stops during sleep. In 2025, Wegovy also gained an indication for a form of fatty liver disease known as MASH, short for metabolic dysfunction-associated steatohepatitis.

Third, long-term data arrived. Three-year results from the SURMOUNT-1 program reported a 94 percent lower rate of progression from prediabetes to type 2 diabetes among participants who stayed on tirzepatide compared with placebo, alongside evidence that weight returns after stopping.

Taken together, the conversation has moved from “which loses more weight” to “which outcomes matter for this person,” which is exactly where a medical decision should live. The sections below follow that shift.

How does Wegovy work for weight loss?

Wegovy contains semaglutide, a laboratory-made molecule that imitates GLP-1, short for glucagon-like peptide-1, a hormone your small intestine releases within minutes of eating. Natural GLP-1 survives in the bloodstream for only about two minutes before enzymes break it down. Semaglutide is chemically altered so it binds to a blood protein called albumin and resists that breakdown, which is why one injection lasts a week.

The hormone works on several fronts at once. In the pancreas, it increases insulin release only when blood sugar is high, which is why it rarely causes low blood sugar on its own. In the stomach, it slows emptying, so a meal sits longer and fullness arrives sooner. In the brain, particularly the hypothalamus and brainstem regions that regulate appetite, it dampens hunger signals and quiets what many patients describe as “food noise,” the constant background pull toward eating. Trial participants eating from unrestricted buffets consumed noticeably fewer calories without being told to.

The pivotal trial, STEP 1, randomized 1,961 adults with obesity or overweight (and without diabetes) to weekly semaglutide or placebo, both with lifestyle counseling, for 68 weeks. The semaglutide group lost 14.9 percent of starting body weight on average; the placebo group lost 2.4 percent. Roughly one in three semaglutide participants lost 20 percent or more.

Two points are easy to miss. Weight loss in these trials continued for roughly a year before flattening, so the first months tell you little about the final result. And every trial arm included diet and activity support; the medicine was tested as an addition to lifestyle change, not a replacement for it.

The same molecule, at a different approved dose range, is sold as Ozempic for type 2 diabetes. The weight-management label is Wegovy.

How Zepbound works: the dual-hormone difference

Zepbound contains tirzepatide, and the one-sentence difference from semaglutide is this: tirzepatide activates two gut-hormone receptors rather than one. Alongside GLP-1, it mimics GIP, short for glucose-dependent insulinotropic polypeptide, another hormone released after meals that helps the body store energy and release insulin.

GIP’s role in weight is still being worked out, and honest researchers say so. In people with obesity, the GIP system appears partly resistant, and early experiments suggested that blocking GIP, not boosting it, might help. Tirzepatide’s results overturned that expectation. Current thinking is that GIP activity in the brain adds to appetite suppression, improves how fat tissue handles energy, and may blunt the nausea that GLP-1 alone can cause, allowing higher effective GLP-1 activity to be tolerated. That last idea is a hypothesis supported by animal and early human data, not a settled fact.

Like semaglutide, tirzepatide is attached to a fatty-acid chain that binds albumin, giving it a half-life of about five days and a weekly schedule.

Its pivotal weight trial, SURMOUNT-1, randomized 2,539 adults with obesity or overweight without diabetes to one of three tirzepatide doses or placebo for 72 weeks. Average weight loss ranged from about 15 percent at the lowest studied dose to 20.9 percent at the highest, against 3.1 percent with placebo. More than half of participants at the higher doses lost at least 20 percent of body weight, a threshold previously seen mainly after bariatric surgery.

The medicine is also sold as Mounjaro for type 2 diabetes, a distinction covered in its own section below. Whichever label is on the box, the molecule and the mechanism are identical.

Wegovy vs Zepbound: what the evidence actually says, graded

Not all evidence carries the same weight, so it helps to sort the claims by strength before comparing them.

Strongest: large, randomized, placebo-controlled trials. STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) both enrolled around 2,000 or more participants, randomly assigned treatment, blinded participants and investigators, and followed people for well over a year. Their weight-loss figures are about as reliable as this kind of medicine research gets. SELECT, the cardiovascular trial of semaglutide, randomized 17,604 adults and tracked hard outcomes such as heart attacks over an average of roughly 40 months. That is top-tier evidence for a benefit beyond weight.

Strong with a caveat: the head-to-head trial. SURMOUNT-5 is a randomized comparison, which is far better than placing separate trials side by side. Its weakness is the open-label design. Knowing which medicine you are on can nudge how you report nausea or how hard you work at diet, though it is unlikely to produce a six-and-a-half-point gap on a scale by itself.

Moderate: outcome trials for specific conditions. SURMOUNT-OSA (sleep apnea) and the MASH liver trials were randomized but smaller and shorter than SELECT, and some used surrogate measures like breathing-event counts or liver biopsy findings rather than events such as death.

Weaker: observational data. Insurance-database studies comparing people prescribed each medicine in routine care have generally echoed the trial ranking, but people are not randomized in real life; those prescribed one medicine may differ in health, income or motivation from those prescribed the other.

Weakest: anecdote. A video of one person’s twelve-week transformation tells you about one person, selected for posting.

What the evidence does not yet include is a randomized head-to-head trial of heart attacks, strokes or deaths between the two molecules. A tirzepatide cardiovascular outcomes trial is under way; until it reports, claims that one medicine “protects your heart better” than the other are speculation.

Does Wegovy have better results than Zepbound?

On the single question of average weight loss, the answer is no. Zepbound produced greater weight reduction in the one trial designed to compare them directly, and the gap was not subtle.

In SURMOUNT-5, after 72 weeks, participants on tirzepatide had lost 20.2 percent of their starting weight on average, compared with 13.7 percent on semaglutide. For someone starting at 250 pounds, that is roughly a 50-pound loss versus 34. Waist circumference fell by about 18 centimeters with tirzepatide versus 13 with semaglutide, roughly the difference between two belt notches and three. Nearly a third of tirzepatide participants lost 25 percent or more of body weight; about one in six semaglutide participants did.

A few nuances keep this from being a simple verdict.

• Both groups lost a clinically meaningful amount. A 13.7 percent average loss would have been headline news five years ago, and it exceeds the 5 to 10 percent range at which blood pressure, blood sugar and joint pain measurably improve.
• Averages hide spread. Some semaglutide participants outperformed some tirzepatide participants. Individual response varies for reasons that are not yet predictable from a blood test.
• The trial excluded people with diabetes. In people with type 2 diabetes, both medicines produce somewhat smaller weight loss, and the relative gap may differ.
• Discontinuation because of side effects was similar and low in both groups, about 6 percent with tirzepatide and 8 percent with semaglutide.

So “better results” depends on which result you mean. If the goal is the largest expected drop in weight, the evidence favors Zepbound. If the goal is a documented reduction in cardiovascular events for someone who already has heart disease, Wegovy currently holds the only randomized proof. For a person with sleep apnea, the sleep-apnea indication sits with Zepbound. The best medicine is the one whose proven benefit matches the problem you are trying to treat.

Wegovy vs Zepbound at a glance

The table pulls the headline facts into one place. Dose levels and schedules are deliberately omitted; those are set by the prescriber and vary by person.

Feature	Wegovy	Zepbound
Active molecule	Semaglutide	Tirzepatide
Receptors activated	GLP-1	GLP-1 and GIP
Schedule	Weekly injection under the skin	Weekly injection under the skin
First US weight approval	June 2021	November 2023
Pivotal weight trial, average loss vs placebo	STEP 1: 14.9% vs 2.4% at 68 weeks	SURMOUNT-1: up to 20.9% vs 3.1% at 72 weeks
Head-to-head (SURMOUNT-5, 72 weeks)	13.7%	20.2%
Additional approved uses (US)	Reduce major cardiovascular events in adults with heart disease and overweight or obesity; MASH liver disease	Moderate-to-severe obstructive sleep apnea in adults with obesity
Randomized proof of fewer heart attacks and strokes	Yes (SELECT)	Not yet; trial ongoing
Most common side effects	Nausea, diarrhea, vomiting, constipation, abdominal pain	Nausea, diarrhea, vomiting, constipation, abdominal pain, injection-site reactions
Same molecule marketed for type 2 diabetes as	Ozempic	Mounjaro
Boxed warning	Thyroid C-cell tumors in rodents; not for people with a personal or family history of medullary thyroid cancer or MEN2	Same

Two cautions when reading it. The pivotal-trial figures come from separate studies with different populations and durations, so the SURMOUNT-5 row is the only fair side-by-side number. And an approved indication reflects which trials a company chose to run and complete, not proof that the other medicine lacks the effect. Semaglutide, for instance, has published sleep-apnea and liver data, and tirzepatide has shown improvements in cardiovascular risk markers; what each lacks is the specific completed trial that regulators require.

Beyond the scale: heart, sleep, liver and diabetes prevention

The most important recent change in this field is that “weight-loss drug” has become an incomplete description. Both medicines now carry evidence for outcomes that physicians care about more than pounds.

Heart. SELECT enrolled adults aged 45 and older with established cardiovascular disease and a BMI of 27 or above, none of whom had diabetes. Over about three and a half years, 6.5 percent of those on semaglutide had a major cardiovascular event compared with 8.0 percent on placebo, a 20 percent relative reduction. Interestingly, the benefit appeared early and was not fully explained by how much weight people lost, pointing to direct effects on inflammation and blood vessels. This is randomized, hard-outcome evidence, the kind that changes guidelines.

Sleep. In the two SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index, the number of breathing interruptions per hour of sleep, by roughly 25 to 29 events per hour, compared with about 5 with placebo, over 52 weeks. Many participants moved from severe disease to mild. Daytime sleepiness and blood pressure also improved.

Liver. MASH is fat-driven liver inflammation that can scar the liver. Semaglutide’s approval rests on biopsy-confirmed resolution of inflammation in a significantly larger share of treated participants than placebo. Tirzepatide has shown similar biopsy findings in a smaller phase 2 study.

Diabetes prevention. Among SURMOUNT-1 participants with prediabetes who continued tirzepatide for three years, progression to type 2 diabetes was 94 percent less common than with placebo. Semaglutide showed a comparable pattern in the STEP program over shorter follow-up.

Blood pressure, triglycerides and markers of inflammation improved with both medicines in essentially every trial. Joint pain from knee osteoarthritis eased in a dedicated semaglutide trial. None of this guarantees an outcome for any individual; it describes average effects in trial populations that your clinician will weigh against your own history.

What are the common side effects of weight loss drugs like these?

The honest summary is that both medicines bother the gut, mostly early, mostly mildly, and in a similar way. In trials, somewhere between four and seven in ten participants reported at least one gastrointestinal symptom, usually around the time the dose was being stepped up.

The most frequent complaints, for both Wegovy and Zepbound:

• Nausea, reported by roughly 25 to 45 percent of participants depending on the trial and dose, typically peaking in the first weeks after each increase and then settling.
• Diarrhea and constipation, often alternating; slower stomach emptying and reduced food intake change bowel rhythm.
• Vomiting, less common than nausea but the symptom most likely to lead to a dose pause.
• Abdominal pain, bloating, belching and acid reflux.
• Fatigue, headache and dizziness, partly from eating and drinking less.
• Injection-site redness or itching, somewhat more often reported with tirzepatide.
• Hair shedding, a temporary response to rapid weight loss rather than a direct drug effect, seen with both.

In SURMOUNT-5, the side-effect profiles of the two medicines were broadly comparable, and the share of people who stopped treatment because of side effects was low for both. Across the separate placebo-controlled programs, nausea and vomiting rates look roughly similar between molecules, which argues against the popular claim that one is dramatically “gentler.”

Mechanism explains most of it. A stomach that empties slowly feels full for longer, and that fullness tips into nausea if a meal is large, fatty or rushed. People in trials who ate smaller portions, stopped at the first signal of fullness and kept up fluids tended to report fewer problems, though this is practical clinical experience rather than randomized evidence.

What the gut symptoms rarely are: a sign the medicine is “working harder.” Weight loss in trials did not track with how nauseated participants felt. Persistent vomiting, inability to keep fluids down, or symptoms that worsen rather than settle are reasons to contact the prescriber, not to push through.

Serious but uncommon risks both medicines share

Because semaglutide and tirzepatide act on the same hormone system, their safety labels read almost identically on the serious items. Knowing them is not fear-marketing; it is how informed consent works.

Thyroid C-cell tumors. Both carry a boxed warning because rodents given these medicines for long periods developed thyroid C-cell tumors. Whether this translates to humans is unknown; decades of GLP-1 use have not produced a clear signal, but the data cannot rule out a small effect. Both are contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.

Pancreatitis. Inflammation of the pancreas occurred in a small number of trial participants. Severe, persistent upper-abdominal pain that may spread to the back is the warning sign.

Gallbladder disease. Rapid weight loss itself raises the risk of gallstones, and both labels list gallbladder problems; in STEP 1, about 2.6 percent of semaglutide participants had a gallbladder-related event versus 1.2 percent on placebo.

Kidney injury from dehydration. Vomiting and diarrhea can drop fluid levels enough to strain the kidneys, particularly in people already taking diuretics or blood-pressure medicines.

Low blood sugar. Rare when used alone, but a real risk in combination with insulin or sulfonylurea diabetes tablets, which a prescriber may need to adjust.

Slowed stomach emptying and anesthesia. Anesthesia societies now ask patients to tell the surgical team they are taking these medicines because food can remain in the stomach longer, raising aspiration risk during sedation.

Mood changes. Labels advise monitoring for depression or suicidal thoughts. Large reviews have not found an increase compared with placebo, but caution remains standard.

Eye disease in diabetes. Semaglutide was linked to worsening of existing diabetic retinopathy in a diabetes trial, likely from rapid blood-sugar improvement; people with retinopathy need eye monitoring.

Pregnancy. Neither medicine is recommended during pregnancy, and the labels advise stopping ahead of a planned pregnancy on a timeline the prescriber sets. The tirzepatide label also notes that oral contraceptives may be absorbed less reliably for a period after starting or increasing the dose; anyone relying on them should raise this with their clinician.

Who is a good candidate for Zepbound or Wegovy?

The labels for the two medicines define eligibility the same way. Both are approved for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnea, used alongside a reduced-calorie diet and increased physical activity. BMI is weight in kilograms divided by height in meters squared; it is a blunt screening tool, and clinicians increasingly look at waist circumference, metabolic lab results and the presence of complications rather than the number alone. Wegovy is additionally approved for some adolescents aged 12 and older with obesity; Zepbound is approved only for adults.

Beyond the label, a few factors shape the conversation with a prescriber.

• Existing heart disease tilts toward Wegovy, because it alone has randomized proof of fewer cardiovascular events.
• Diagnosed moderate-to-severe sleep apnea with obesity tilts toward Zepbound, which carries that indication.
• A need for the largest expected weight reduction, for example before a joint replacement or to reach a surgical BMI threshold, favors tirzepatide on the trial numbers.
• Type 2 diabetes changes the picture: the same molecules are prescribed under the Ozempic and Mounjaro labels, and glucose-lowering medicines may need adjusting.
• A history of pancreatitis, severe gastrointestinal disease such as gastroparesis, or the thyroid conditions above argues against either.
• Planning pregnancy within the coming months argues for waiting.

Readiness matters as much as eligibility. These medicines work best for people prepared to treat obesity as a long-term condition, keep follow-up appointments during dose escalation, and protect muscle with resistance exercise and adequate protein while eating less. Someone seeking a six-week result before an event is, by the evidence, a poor candidate for either.

None of these considerations is a decision. They are the questions a prescribing clinician will walk through, with access to your history, your other medicines and your lab results.

Mounjaro vs Zepbound (and Ozempic vs Wegovy): same molecule, different label

Few things confuse readers more than the four brand names, so here is the plain version. Mounjaro and Zepbound are the same drug, tirzepatide, made by the same company, in the same pen format. Ozempic and Wegovy are the same drug, semaglutide, from the same company. The brand name tells you which condition the regulator approved it for and which trials supported that approval.

Mounjaro was approved in May 2022 for improving blood-sugar control in adults with type 2 diabetes, after the SURPASS trials. Zepbound was approved in November 2023 for chronic weight management, after the SURMOUNT trials, and later for sleep apnea. The approved dose ranges overlap substantially. In the United Kingdom and several other countries, the weight-management product is also marketed under the Mounjaro name, which explains why “mounjaro vs zepbound” is a common search in the US: people see British news reports about Mounjaro for weight loss and wonder whether it is a different medicine. It is not.

The semaglutide pair follows the same logic. Ozempic, approved in 2017 for type 2 diabetes, became widely known for weight loss as a side effect. Wegovy, approved in 2021, delivers semaglutide specifically studied for weight management, and its approved maximum dose is higher than Ozempic’s.

Why does the distinction matter if the molecules are identical?

• Insurance coverage usually follows the label, and a diabetes product prescribed for weight alone is an off-label use.
• The side-effect, warning and monitoring information is the same across the pair, so a safety fact about Ozempic applies to Wegovy and vice versa.
• Clinical trial results are often reported by brand, which can make one “look” different from its twin when only the population studied differed.

Off-label prescribing is legal and common in medicine, and whether it is appropriate for a given person is a judgment that belongs to the treating clinician, weighing evidence, the person’s conditions and coverage realities. What never changes is the molecule inside the pen.

What happens when you stop, and why muscle and habits matter

The least welcome finding across both drug programs is also the most consistent: when the medicine stops, appetite returns, and so does much of the weight.

In the STEP 1 extension, participants who discontinued semaglutide after 68 weeks regained about two-thirds of their lost weight within the following year. In SURMOUNT-4, people who had lost an average of about 21 percent on tirzepatide were randomized either to continue or to switch to placebo. Over the next 52 weeks, the continuing group lost a further 5.5 percent or so; the placebo group regained roughly 14 percent of body weight. These were randomized data, so the regain was not a matter of weak willpower; it was biology reasserting itself once the hormonal signal was withdrawn.

This is why clinicians describe both medicines as treatments for a chronic condition, much like blood-pressure tablets, rather than courses to complete. Stopping, pausing or lowering the dose is sometimes appropriate, for pregnancy planning, surgery, side effects or personal choice, but it should be a planned decision made with the prescriber, with a strategy for the appetite rebound.

Two things appear to protect the result, though the evidence here is observational and expert consensus rather than randomized.

Muscle. Roughly a quarter to a third of weight lost on these medicines comes from lean tissue, a proportion similar to diet-induced loss. Resistance training two or three times a week and a protein intake at the higher end of normal are standard advice to preserve strength, especially for adults over 60.

Habits. Participants who used the quieter appetite to build regular meals, more vegetables and daily movement had a better chance of keeping weight off in follow-up analyses. The medicine lowers the volume on hunger; what you practice during that quiet period is what remains when the volume comes back up.

Common myths about Wegovy and Zepbound, checked against the evidence

Viral claims travel faster than trial publications. Here are the ones that come up most, measured against what the studies show.

“Zepbound is twice as strong as Wegovy.” The head-to-head trial found about 47 percent more average weight loss with tirzepatide (20.2 versus 13.7 percent), a meaningful advantage but not double, and both groups lost a clinically important amount.

“Wegovy is gentler on the stomach.” Trial data do not support a large difference. Nausea, vomiting and diarrhea rates were broadly similar in SURMOUNT-5 and across the placebo-controlled programs. Individual experience varies, which is a reason to report symptoms, not to assume one molecule will spare you.

“If you feel sick, it means the drug is working.” Weight loss did not track with nausea in the trials. Persistent vomiting is a safety issue, not a progress marker.

“These medicines melt fat without changing anything else.” Every pivotal trial paired the medicine with lifestyle counseling, and lean mass is lost alongside fat unless protected by exercise and protein.

“You can take it for six months and keep the result.” Randomized stop-versus-continue data show substantial regain within a year of stopping with both molecules.

“Compounded versions are the same thing.” Compounded products are mixed by pharmacies rather than manufactured by the drug maker and are not FDA-approved; the FDA does not verify their safety, effectiveness or quality, and it has reported dosing errors and adverse events tied to them. During the official shortage periods, compounding was permitted under specific rules; the shortages for both semaglutide and tirzepatide have since been declared resolved, which removed the main legal basis for routine compounding of these molecules. “Research peptides” sold online are not approved medicines for any human use and are not for sale or self-use.

“Zepbound causes thyroid cancer.” The boxed warning reflects rodent findings. Human surveillance over many years of GLP-1 use has not confirmed an increase, though the possibility of a small effect cannot be excluded, which is why people with the specific hereditary thyroid conditions are excluded.

“One of them protects your heart more.” Only semaglutide has completed a randomized cardiovascular outcomes trial. Tirzepatide’s is ongoing; until it reports, the comparison is unknown, not settled.

When to see a doctor while taking Wegovy or Zepbound

Most side effects of these medicines are a nuisance that fades. A short list is not. Everyone using either pen should know which symptoms mean a same-day call to the prescriber and which mean emergency care.

Seek emergency care if you have:

• Severe, persistent pain in the upper abdomen, especially if it spreads to the back and comes with vomiting; this can signal pancreatitis.
• Signs of a serious allergic reaction: swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash with dizziness.
• Confusion, fainting, or a very rapid heartbeat, particularly after prolonged vomiting or diarrhea.
• Symptoms of low blood sugar that do not improve with sugar, such as shakiness, sweating, confusion or loss of consciousness, if you also take insulin or sulfonylureas.

Contact your prescriber promptly if you notice:

• Vomiting or diarrhea lasting more than a day, or an inability to keep fluids down; dehydration can injure the kidneys.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools, which may point to gallbladder problems.
• A lump or swelling in the neck, hoarseness, trouble swallowing or persistent shortness of breath; the labels ask that these be evaluated.
• New or worsening low mood, anxiety or any thoughts of self-harm.
• Changes in vision, particularly if you have diabetes.
• Constipation lasting more than a week or severe bloating with no bowel movement, which can rarely indicate a blocked bowel.
• A positive pregnancy test, a plan to become pregnant, or a scheduled surgery or procedure requiring sedation.

Routine follow-up matters as much as red flags. Dose escalation, blood-pressure medicines, diabetes medicines and thyroid or kidney monitoring all need a clinician’s eye, and weight loss that stalls or that feels too fast deserves a conversation rather than a self-adjusted dose. Never change the dose, skip ahead, or stop either medicine without speaking to the person who prescribed it. The comparison in this article is background for that conversation, not a substitute for it.

Frequently asked questions

Does Wegovy have better results than Zepbound?

Not for average weight loss. In the SURMOUNT-5 randomized trial, Zepbound (tirzepatide) produced 20.2 percent weight reduction over 72 weeks compared with 13.7 percent for Wegovy (semaglutide). Wegovy, however, has the only completed randomized trial showing fewer heart attacks and strokes in people with existing heart disease. Which result matters more depends on your health history, and that judgment belongs to your prescriber.

Who is a good candidate for Zepbound?

Zepbound is approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or sleep apnea, used alongside diet and activity changes. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. People with a history of medullary thyroid cancer, MEN2 or pancreatitis, and those planning pregnancy, generally are not candidates. A clinician makes the final assessment.

What are the common side effects of taking weight loss drugs like Wegovy and Zepbound?

Nausea, diarrhea, vomiting, constipation and abdominal pain are the most frequent for both, affecting a large share of trial participants, mostly during dose increases and usually easing over weeks. Fatigue, headache, reflux and injection-site reactions also occur. Rare but serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury and low blood sugar when combined with insulin.

How does Wegovy work for weight loss?

Wegovy contains semaglutide, which mimics GLP-1, a gut hormone released after eating. It slows stomach emptying so meals feel more filling, acts on appetite centers in the brain to reduce hunger and food cravings, and prompts insulin release only when blood sugar is high. In the STEP 1 trial, this produced an average 14.9 percent weight loss over 68 weeks versus 2.4 percent with placebo.

What is the difference between Mounjaro vs Zepbound?

They contain the same medicine, tirzepatide, from the same manufacturer. Mounjaro is the label approved for blood-sugar control in type 2 diabetes; Zepbound is the label approved for chronic weight management and obstructive sleep apnea. In some countries, including the UK, the weight-management product is also sold under the Mounjaro name. Side effects, warnings and mechanism are identical.

Is Zepbound safer than Wegovy?

The evidence does not show a clear safety advantage for either. In the head-to-head trial, gastrointestinal side effects and the rate of stopping treatment because of side effects were similar and low for both. Both carry the same boxed thyroid warning and the same list of rare serious risks. Individual tolerance varies, which is something to monitor with your prescriber rather than predict from the brand name.

Can you switch from Wegovy to Zepbound?

Switching between GLP-1-based medicines does happen in clinical practice, usually because of side effects, a plateau or coverage changes. There is no randomized trial defining the best way to do it, and the transition typically involves restarting dose escalation with the new medicine. Any switch, including its timing and dosing, must be planned by the prescribing clinician; never combine the two or self-adjust.

How long does it take to see results on Wegovy or Zepbound?

In trials, measurable weight loss began within the first month and continued for roughly a year before leveling off, because doses are increased gradually and appetite effects build. Early weeks tell you little about the final result. Clinicians often reassess after several months at the full dose; the labels note that people who lose less than about 5 percent by then may not benefit from continuing.

Do Wegovy and Zepbound cause muscle loss?

Some lean tissue is lost with any substantial weight reduction, and body-composition substudies suggest roughly a quarter to a third of weight lost on these medicines is lean mass, similar to diet-induced loss. Resistance exercise two or three times weekly and adequate protein are the standard recommendations to protect muscle, though this guidance rests on expert consensus and observational data rather than randomized trials.

Are compounded semaglutide or tirzepatide the same as Wegovy and Zepbound?

No. Compounded versions are not FDA-approved, and the FDA does not review their safety, quality or effectiveness; it has reported dosing errors and adverse events linked to them. Compounding was allowed under shortage rules, but both shortages have been declared resolved. Products marketed online as research peptides are not approved for human use and are not for sale or self-use. Discuss any product with your clinician.

References

• MedlinePlus: Semaglutide Injection
• MedlinePlus: Tirzepatide Injection
• PubMed: SURMOUNT-5 trial, tirzepatide versus semaglutide for obesity
• Cleveland Clinic: GLP-1 Agonists

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.